Orgenesis stock fell 36.36 percent on October 6

Published on 10/07/2026 at 03:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Orgenesis stock traded at USD 0.35 on October 6, 2026, while its market value stood at USD 3.4 million. A June filing highlights dilution risk.

ORGS, US68619K3032, Illustration mit AI erstellt.

Orgenesis (ISIN US68619K3032) was last at USD 0.35 on the OTC Expert Market on October 6, 2026, down 36.36 percent from the prior close of USD 0.55. The move puts the small biotechnology company back in front of investors through a sharp one-session repricing rather than a newly reported operating result.

Stock loses ground in October

The reference price fell USD 0.20 during the session covered by the quote, while Orgenesis' market capitalization stood at USD 3.4 million on October 6, 2026. The price and market value point to a micro-cap security in which even a small absolute move can create a large percentage change.

That comparison matters because the latest annual figures listed by Simply Wall St are from fiscal year 2024. Revenue was USD 1.04 million, compared with USD 0.53 million in fiscal year 2023, while earnings were negative USD 48.16 million for fiscal year 2024.

Capital structure remains central

The most concrete corporate development in the recent filing record is dated June 2, 2026. According to StockTitan, Orgenesis reported that stockholders approved an increase in authorized common shares from 14.583 million to 150.0 million, alongside a share issuance proposal tied to a convertible loan agreement.

The same filing places the stock on the OTC Expert Market, a materially different trading setting from a Nasdaq quotation. For investors, the authorized-share increase is the key counterweight to the company's therapy platform because future financing or conversion activity can affect the ownership percentage represented by each existing share.

Point of care platform drives strategy

Orgenesis describes its business as a platform for cell and gene therapies, with point-of-care technologies designed to support automated and standardized processing close to the patient. Its model combines therapies, technology partners and a network of hospitals, research institutions and academic collaborators.

That operating model gives the company a clear strategic focus, but the financial comparison remains demanding: fiscal 2024 revenue of USD 1.04 million stood beside negative USD 48.16 million in earnings. The October 6 price move therefore leaves capital structure, funding capacity and execution on the therapy platform as the central investor questions.